Gilead Sciences: Lymphoma, Large B-Cell, Diffuse trials
The registry lists 11 Lymphoma, Large B-Cell, Diffuse studies with Gilead Sciences as lead sponsor. 0 are open to participants now and 5 have results posted.
Phase 1 5Phase 2 7Phase 3 3No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell LymphomaCompletedNCT03391466Phase 3Results posted
- Study of Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)CompletedNCT02926833Phase 1/2Results posted
- Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin LymphomaCompletedNCT02348216Phase 1/2Results posted
- Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic MalignanciesTerminatedNCT01799889Phase 2Results posted
- Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic MalignanciesTerminatedNCT01796470Phase 2Results posted
- Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and AdolescentsWithdrawnNCT03349346Phase 1
- Axicabtagene Ciloleucel Expanded Access StudyApproved for marketingNCT03153462
- Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHLWithdrawnNCT01101581Phase 1/2
- Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's LymphomaCompletedNCT00596804Phase 1/2
- Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's LymphomaStatus unknownNCT00003338Phase 2/3
- Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's LymphomaStatus unknownNCT00003337Phase 3